An analysis of a multiple biomarker panel to better predict prostate cancer metastasis after radical prostatectomy.

摘要: A plethora of individual candidate biomarkers for predicting biochemical relapse in localized prostate cancer (PCa) have been proposed. Combined may improve prognostication, and ensuring validation against more clinically relevant endpoints are required. The Australian PCa Research Centre NSW has contributed to numerous studies molecular associated with relapse. In the current study, these were re-analyzed relapse, metastatic death extended follow-up. Biomarkers significance then used develop a combined prognostic model clinical outcomes validated large independent cohort. discovery cohort (n = 324) was based on 12 median follow-up 16 years. Seven significantly Three metastases: AZGP1, Ki67 PML. Only AZGP1 death. their combinational forms, as dual BM signature most robust predictor (AUC 0.762). AZPG1 an 347 patients. predicted metastasis univariable (HR 7.2, 95% CI, 1.6-32; p 0.01) multivariable analysis 5.4, 1.2-25; 0.03). biomarker marginally improved risk prediction compared alone 0.758 versus 0.738, < 0.001). Our findings indicate that is not adequate surrogate or offers small benefit over alone.